cliramitug

all catalysts(0)

nothing on the calendar yet

News(2)

• 5 companies advancing ATTR assets in the wake of Wainua’s fail
  The Phase 3 failure of AstraZeneca and Ionis Pharmaceuticals’ antisense therapy in transthyretin amyloid cardiomyopathy last month left the space reeling—and readjusting. BioSpace looks at five con…
  biospace · 18d ago
• Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drug
  Royalty Pharma has secured a stake in another transthyretin-mediated amyloidosis drug, this time paying $125 million upfront to Neurimmune for a cut of the sales of its AstraZeneca-partnered med.
  fiercebiotech · 29d ago